Venolife Duo, 1000 mg 30 pcs

Pharmacotherapeutic group:Venotonizing and venoprotective agent.

CodeATH: C05CA53

Pharmacological properties

Pharmacodynamics.

The combination of diosmin + hesperidin has venotonic and angioprotective properties. The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to the indices of venous hemodynamics. Statistically reliable dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. An optimal dose-effect ratio is observed when taking 1000 mg per day.

The combination of diosmin + hesperidin increases venous tone: venous occlusion plethysmography showed a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders, after therapy with the drug there was (statistically significant in comparison with placebo) an increase of capillary resistance evaluated by angiostereometry.

Pharmacokinetics

The main excretion of the drug is in the feces. With the urine, on average, about 14% of the taken amount of the drug is excreted. The elimination half-life is 11 hours. The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Indications

Venolife Duo is indicated for the treatment of symptoms of chronic vein disease (elimination and relief of symptoms).

The therapy of symptoms of venous and lymphatic insufficiency:

– pain;

– cramping of the lower extremities;

– feeling of heaviness and tumescence in the legs;

– “tired” legs.

The therapy of manifestations of venous and lymphatic insufficiency:

– swelling of the lower extremities;

– trophic changes in the skin and subcutaneous tissue;

– venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

One tablet contains:

Active substance:

Purified micronized flavonoid fraction (in terms of anhydrous substance) containing diosmin (90%) and other flavonoids (10%) – 500 mg or 1000 mg.

Auxiliary substances:

gelatin,

magnesium stearate,

microcrystalline cellulose,

sodium carboxymethyl starch,

talc.

Film coating:premixed “Vivacote” [macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, iron oxide red dye, iron oxide yellow dye], sodium lauryl sulfate.

How to take, the dosage

Ingestion.

The recommended dose for veno-lymphatic insufficiency is -1000 mg per day, preferably in the morning, with a meal.Tablets should be swallowed with water.

The risk on the tablet is intended solely for division in order to facilitate swallowing.

The duration of treatment may be several months (up to 12 months). The course of treatment may be repeated if the symptoms recur, upon the doctor’s recommendation.

The recommended dose for acute hemorrhoids is 3000mg per day (1000mg morning, afternoon and evening) for 4 days, then 2000mg per day (1000mg morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1000 mg daily.

Interaction

No clinical studies on the study of interactions of diosmin+hesperidinz combination with other drugs have been conducted. To date, no cases of drug interactions have been reported.

Special Instructions

Consultation with your doctor is recommended before starting to take Venolife Duo.

Venolife Duo is not a substitute for specific treatment of other anal disorders when hemorrhoids are exacerbated and the duration of treatment should not exceed the time stated in the “Instructions for Use and Doses” section. If symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will determine further therapy.

Please see your doctor immediately if your condition worsens or does not improve with treatment.

Influence on ability to drive vehicles, mechanisms

There have been no clinical studies to study the effect of diosmin + hesperidin combination on the ability to drive and perform work requiring high speed mental and physical reactions. However, based on the available safety data, it can be concluded that diosmin + hesperidin have no effect (no significant effect) on these processes.

Contraindications

Hypersensitivity to the active ingredient or excipients contained in the drug.

It is not recommended to take the drug in lactating women.

Side effects

The side effects of diosmin+hesperidin combination observed in clinical trials were mild in severity. Gastrointestinal disorders (diarrhea, dyspepsia, nausea, vomiting) were mostly observed.

The following side effects have been reported while taking diosmin+hesperidin combination, in the following grading: Very common (≥1/10); common (≥1/100,< 1/10); infrequent (≥1/1,000, < 1/100); rare (≥1/10,000, < 1/1,000); extremely rare(< 1/10,000), unspecified frequency (frequency cannot be calculated from available data).

From the central nervous system:

Rarely: dizziness, headache, general malaise.

Gastrointestinal tract:

Often: diarrhea, dyspepsia, nausea, vomiting.

Infrequent: colitis.

Unspecified frequency: abdominal pain.

Skin side:

Rarely: skin rash, skin itching, urticaria.

Unspecified frequency: isolated swelling of the face, lips, eyelids.

In exceptional cases, angioedema.

Inform your physician if you experience any adverse reactions, including those not mentioned in these instructions, as well as changes in laboratory values during therapy.

Overdose

No cases of overdose have been described. Seek medical attention immediately if you overdose.

Pregnancy use

Pregnancy

Animal experiments have shown no teratogenic effects. To date, there have been no reports of adverse effects when using the drug in pregnant women.

Breastfeeding

In the absence of data concerning excretion of the drug with the breast milk, breastfeeding women are not recommended to take the drug. Effect on reproductive function. Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.

Similarities

Venarus, Detralex, Phlebaven, Detravenol, Diosmin+Hesperidin, Troxactiv